World Journal of *Gastroenterology*

World J Gastroenterol 2024 February 7; 30(5): 424-515





Published by Baishideng Publishing Group Inc

WUG

World Journal of Gastroenterology

Contents

Weekly Volume 30 Number 5 February 7, 2024

EDITORIAL

424 Leveraging machine learning for early recurrence prediction in hepatocellular carcinoma: A step towards precision medicine

Ravikulan A, Rostami K

REVIEW

Nicotinamide adenine dinucleotide phosphate oxidase in pancreatic diseases: Mechanisms and future 429 perspectives

Bi YW, Li LS, Ru N, Zhang B, Lei X

ORIGINAL ARTICLE

Retrospective Study

440 Evaluation of the efficacy and safety of endoscopic band ligation in the treatment of bleeding from mild to moderate gastric varices type 1

Deng Y, Jiang Y, Jiang T, Chen L, Mou HJ, Tuo BG, Shi GO

450 Development and validation of a prediction model for early screening of people at high risk for colorectal cancer

Xu LL, Lin Y, Han LY, Wang Y, Li JJ, Dai XY

462 Diagnosis and treatment experience of atypical hepatic cystic echinococcosis type 1 at a tertiary center in China

Li YP, Zhang J, Li ZD, Ma C, Tian GL, Meng Y, Chen X, Ma ZG

Basic Study

471 Recombinant adeno-associated virus 8-mediated inhibition of microRNA let-7a ameliorates sclerosing cholangitis in a clinically relevant mouse model

Hua H, Zhao QQ, Kalagbor MN, Yu GZ, Liu M, Bian ZR, Zhang BB, Yu Q, Xu YH, Tang RX, Zheng KY, Yan C

485 Bile acids inhibit ferroptosis sensitivity through activating farnesoid X receptor in gastric cancer cells Liu CX, Gao Y, Xu XF, Jin X, Zhang Y, Xu Q, Ding HX, Li BJ, Du FK, Li LC, Zhong MW, Zhu JK, Zhang GY

CASE REPORT

499 Dynamic ultrasonography for optimizing treatment position in superior mesenteric artery syndrome: Two case reports and review of literature

Hasegawa N, Oka A, Awoniyi M, Yoshida Y, Tobita H, Ishimura N, Ishihara S



Contents

World Journal of Gastroenterology

Weekly Volume 30 Number 5 February 7, 2024

LETTER TO THE EDITOR

Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel 509 systemic therapies: Who and Why?

Tonnini M, Solera Horna C, Ielasi L

512 Can serum immunoglobulin G4 levels and age serve as reliable predictors of relapse in autoimmune pancreatitis?

Song JM, Sun SY



Contents

Weekly Volume 30 Number 5 February 7, 2024

ABOUT COVER

Editorial Board Member of World Journal of Gastroenterology, Anca Trifan, MD, PhD, FRCP, FEBG, AGAF, Professor, "Grigore T. Popa" University of Medicine and Pharmacy, "St. Spiridon" University Hospital, Institute of Gastroenterology and Hepatology, Iasi 700111, Romania. ancatrifan@yahoo.com

AIMS AND SCOPE

The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS				
World Journal of Gastroenterology	https://www.wjgnet.com/bpg/gerinfo/204				
ISSN	GUIDELINES FOR ETHICS DOCUMENTS				
ISSN 1007-9327 (print) ISSN 2219-2840 (online)	https://www.wjgnet.com/bpg/GerInfo/287				
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH				
October 1, 1995	https://www.wjgnet.com/bpg/gerinfo/240				
FREQUENCY	PUBLICATION ETHICS				
Weekly	https://www.wjgnet.com/bpg/GerInfo/288				
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT				
Andrzej S Tarnawski	https://www.wjgnet.com/bpg/gerinfo/208				
EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF	POLICY OF CO-AUTHORS				
Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou- Bao Liu (Biliary Tract Disease)	https://www.wjgnet.com/bpg/GerInfo/310				
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE				
http://www.wjgnet.com/1007-9327/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242				
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS				
February 7, 2024	https://www.wjgnet.com/bpg/GerInfo/239				
COPYRIGHT	ONLINE SUBMISSION				
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com				
PUBLISHING PARTNER	PUBLISHING PARTNER'S OFFICIAL WEBSITE				
Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University Biliary Tract Disease Institute, Fudan University	https://www.shca.org.cn https://www.zs-hospital.sh.cn				
© 2024 Baishideng Publishing Group Inc. All rights reserved. 70	41 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA				

E-mail: office@baishideng.com https://www.wjgnet.com



WJG

World Journal of Gastroenterology

Submit a Manuscript: https://www.f6publishing.com

World J Gastroenterol 2024 February 7; 30(5): 424-428

DOI: 10.3748/wjg.v30.i5.424

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

EDITORIAL

Leveraging machine learning for early recurrence prediction in hepatocellular carcinoma: A step towards precision medicine

Abhimati Ravikulan, Kamran Rostami

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Lu GR, China; Morya AK, India

Received: November 21, 2023 Peer-review started: November 21, 2023 First decision: December 5, 2023 Revised: December 19, 2023 Accepted: January 12, 2024 Article in press: January 12, 2024

Published online: February 7, 2024



Abhimati Ravikulan, Kamran Rostami, Department of Gastroenterology, Palmerston North Hospital, Palmerston North 4442, New Zealand

Corresponding author: Abhimati Ravikulan, Doctor, Research Fellow, Researcher, Department of Gastroenterology, Palmerston North Hospital, 50 Ruahine Street, Roslyn, Palmerston North 4442, New Zealand. arav175@aucklanduni.ac.nz

Abstract

The high rate of early recurrence in hepatocellular carcinoma (HCC) post curative surgical intervention poses a substantial clinical hurdle, impacting patient outcomes and complicating postoperative management. The advent of machine learning provides a unique opportunity to harness vast datasets, identifying subtle patterns and factors that elude conventional prognostic methods. Machine learning models, equipped with the ability to analyse intricate relationships within datasets, have shown promise in predicting outcomes in various medical disciplines. In the context of HCC, the application of machine learning to predict early recurrence holds potential for personalized postoperative care strategies. This editorial comments on the study carried out exploring the merits and efficacy of random survival forests (RSF) in identifying significant risk factors for recurrence, stratifying patients at low and high risk of HCC recurrence and comparing this to traditional COX proportional hazard models (CPH). In doing so, the study demonstrated that the RSF models are superior to traditional CPH models in predicting recurrence of HCC and represent a giant leap towards precision medicine.

Key Words: Machine learning; Artificial intelligence; Hepatocellular carcinoma; Hepatology; Early recurrence; Liver resection

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.



WJG https://www.wjgnet.com

Core Tip: This study addresses the crucial issue of early recurrence in hepatocellular carcinoma, emphasizing the significance of aggressive tumour characteristics. random survival forests, a machine learning model, surpasses conventional COX proportional hazard models, offering improved prediction, clinical usefulness, and overall performance. The model's ability to stratify risk facilitates targeted postoperative strategies, showcasing its potential as a guide for personalized patient care.

Citation: Ravikulan A, Rostami K. Leveraging machine learning for early recurrence prediction in hepatocellular carcinoma: A step towards precision medicine. *World J Gastroenterol* 2024; 30(5): 424-428 **URL:** https://www.wjgnet.com/1007-9327/full/v30/i5/424.htm **DOI:** https://dx.doi.org/10.3748/wjg.v30.i5.424

INTRODUCTION

Developing a reliable pre-operative prediction model for postoperative recurrence of hepatocellular carcinoma (HCC) is essential in guiding individualized treatment and prognostication process of HCC.

In this issue of *World Journal of Gastroenterology*, Zeng *et al*[1] endeavour to identify key variables in pre-operative clinical and imaging data using machine learning algorithms to construct multiple risk prediction models for early postoperative recurrence of HCC.

HCC remains a significant challenge in the realm of oncology, particularly due to its propensity for early recurrence following curative resection[2,3]. It is the sixth most common cancer worldwide[4]. Though surgical resection remains the mainstay of curative therapy for HCC, early recurrence of HCC (within 1 year) stands as a substantial barrier to positive patient outcomes[3,5]. Survival rates in early recurrence of HCC can be as low as 25% at 3-5 years post resection[5]. There are no current approved therapeutic regimens available for the recurrence of HCC[6].

This raises a significant need to improve models for the early detection of patients at risk of recurrence. Many factors have been identified in predicting risk of recurrence of HCC[2] and this editorial explores the promising avenue in the quest for precision medicine[1] the development of a machine learning model as highlighted by the authors aimed at predicting early recurrence after surgical intervention[7]. The advent of machine learning provides a unique opportunity to harness vast datasets, identifying subtle patterns and factors that elude conventional prognostic methods[8,9].

Machine learning models, equipped with the ability to analyse intricate relationships within datasets, have shown promise in predicting outcomes in various medical disciplines^[8]. In the context of HCC, the application of machine learning to predict early recurrence holds potential for personalized postoperative care strategies^[10].

Traditionally, predictive models, such as COX proportional hazard (CPH) models, have been employed, but their limitations have spurred the exploration of innovative methodologies[9-11]. This study undertakes a critical examination, comparing the efficacy of random survival forests (RSF) with CPH models in forecasting early recurrence for HCC patients following curative resection.

Drawing from a comprehensive cohort of 4758 patients across two medical centres, this study utilized 15 key features to construct the RSF model. Features encompassed demographic, clinical, and tumour-specific factors. The RSF model was rigorously evaluated for discrimination, calibration, clinical utility, and overall performance, benchmarked against traditional models.

Out of 5686 patients with HCC undergoing definitive surgical therapy at Eastern Hepatobiliary Surgery Hospital (January 2008 to December 2015), 4376 met inclusion criteria. The study included patients with Child-Pugh A cirrhosis or B7 Liver function, without extrahepatic metastases, and complete resection of macroscopic tumour with histological evidence of tumour free margins. Exclusions (n = 1310) were due to preoperative anticancer treatment, history of other malignancies, palliative surgery, loss to follow up within 2 months of surgery, and perioperative death. The training cohort comprised 3370 patients (January 2008 to December 2013), internal validation cohort 1006 patients (January 2014 to December 2015), and external validation cohort 382 patients from Mengchao Hepatobiliary Hospital of Fujian Medical University.

The RSF model was constructed and used as a regression algorithm with faster training and lower estimation bias. This was achieved by using techniques of random forests such as feature and sample bragging. The model was constructed using fifteen factors including age, gender, aetiology, platelet count, albumin, total bilirubin, alpha-fetoprotein (AFP), tumour size, tumour number, microvascular invasion, macrovascular invasion, Edmondson-Steiner grade, tumour capsular, satellite nodules and liver cirrhosis. As 200 survival trees were built, the prediction error was significantly low and at 500 trees constructed, the variable importance for all 15 features was also generated. Utilizing cut-off values (50th and 85th centiles) from the training cohort's risk index, RSF classified patients into low-risk, intermediate-risk, and high-risk groups, providing valuable insights for postoperative follow-up and adjuvant therapy. Kaplan-Meier analysis validated the stratification in all cohorts (P < 0.0001) (Figure 1).

Model performance was assessed across several methods including model discrimination, model calibration, clinical usefulness and overall performance. In training, internal, and external validation cohorts, RSF outperformed existing models with C-index values of 0.725, 0.762, and 0.747, respectively. Overall performance time-dependent Brier (2 years) were 0.147, 0.129, and 0.156. RSF excelled against five other models that follow CPH. Decision curve analysis affirmed RSF's superior net benefit over other models (Table 1).

Zaishidene® WJG | https://www.wjgnet.com

Table 1 Comparison of random survival forests model performance vs 5 other models following Cox proportional hazard format to predict early recurrence

predict carry recurrence							
Performance	Cohort	RSF	ERASL	Korean	AJCC TNM	BCLC	Chinese
Model Discrimination: (Harrell's C- Index)	Training	0.725	0.706	0.658	0.674	0.635	0.684
	Internal	0.762	0.726	0.672	0.711	0.646	0.709
	External	0.747	0.727	0.722	0.711	0.658	0.696
Overall Performance: Time dependent Brier (2 years)	Training	0.147	0.156	0.174	0.160	0.167	0.161
	Internal	0.129	0.143	0.159	0.144	0.154	0.146
	External	0.156	0.162	0.161	0.169	0.180	0.176
Clinical Usefulness: Net benefit at threshold 50%	Training	0.166	0.154	0.093	0.139	0.137	0.137
	Internal	0.121	0.092	0.041	0.095	0.073	0.073
	External	0.206	0.190	0.222	0.185	0.154	0.154

RSF: Random survival forest; ERASL: Early Recurrence After Surgery for Liver tumours; AJCC TNM: American Joint Committee on Cancer tumour-nodemetastasis; BCLC: Barcelona Clinic Liver Cancer stage.




Figure 1 Construction of random survival forests model. 15 factors used to construct random survival forests model in hepatocellular carcinoma patients who underwent R0 resection with variable importance factors emergence and risk stratification applied. HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein.

The RSF model, employing 500 survival trees, showcased superior predictive power. Key factors influencing recurrence were tumour size (which was the most significant risk factor for early recurrence), followed by macrovascular invasion, microvascular invasion, tumour number, and AFP levels.

The limitations to this study include selection bias as the cohort of patients largely had liver disease secondary to hepatitis B, which leaves a large space to question the applicability of these outcomes to other aetiologies of liver disease, and indeed, the RSF model did not consider aetiology and liver cirrhosis as important predictors of recurrence. Further studies will need to be conducted with the RSF model using patients of different aetiologies of liver disease to validate its use across different demographics in predicting HCC recurrence and reduce selection bias.

The user-friendly aspect of the web-tool developed, encompasses multiple complex aspects of the predictive model to increase its application in clinical practice.

In conclusion, the RSF model emerges as a beacon in the quest for precision postoperative care in HCC. Its demonstrated superiority over traditional models, coupled with its ability to stratify risk, ushers in a new era of individualized treatment strategies. The future role of artificial intelligence (AI) in evaluating hepatic diseases holds tremendous promise for revolutionizing diagnostic and treatment approaches. AI technologies, particularly machine learning algorithms, can analyse vast amounts of medical data, including imaging studies, laboratory results, and patient histories, to identify patterns and subtle anomalies that may escape the human eye. In hepatic diseases, AI can play a crucial role in early detection, risk assessment, and personalized treatment planning. Advanced imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, can be enhanced by AI algorithms to provide more accurate and timely diagnoses of liver conditions. Machine learning models can also predict disease progression, helping healthcare professionals tailor interventions based on individual patient profiles.

As we navigate this machine learning odyssey, the RSF model stands poised to redefine the landscape of HCC prognostication and guide clinicians toward more informed and personalized patient care.

CONCLUSION

In conclusion, the RSF model emerges as a beacon in the quest for precision postoperative care in HCC. Its demonstrated superiority over traditional models, coupled with its ability to stratify risk, ushers in a new era of individualized treatment strategies. The future role of AI in evaluating hepatic diseases holds tremendous promise for revolutionizing diagnostic and treatment approaches. AI technologies, particularly machine learning algorithms, can analyse vast amounts of medical data, including imaging studies, laboratory results, and patient histories, to identify patterns and subtle anomalies that may escape the human eye. In hepatic diseases, AI can play a crucial role in early detection, risk assessment, and personalized treatment planning. Advanced imaging techniques, such as MRI and CT scans, can be enhanced by AI algorithms to provide more accurate and timely diagnoses of liver conditions. Machine learning models can also predict disease progression, helping healthcare professionals tailor interventions based on individual patient profiles.

As we navigate this machine learning odyssey, the RSF model stands poised to redefine the landscape of HCC prognostication and guide clinicians toward more informed and personalized patient care.

FOOTNOTES

Author contributions: Ravikulan A wrote the first draft; Rostami K reviewed the manuscript; and both authors finalized the editorial.

Conflict-of-interest statement: The authors declare no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: New Zealand

ORCID number: Abhimati Ravikulan 0009-0000-6702-2958; Kamran Rostami 0000-0002-2114-2353.

S-Editor: Qu XL L-Editor: A P-Editor: Yu HG

REFERENCES

- Zeng J, Zeng J, Lin K, Lin H, Wu Q, Guo P, Zhou W, Liu J. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr 2022; 11: 176-187 [PMID: 35464276 DOI: 10.21037/hbsn-20-466]
- Nevola R, Ruocco R, Criscuolo L, Villani A, Alfano M, Beccia D, Imbriani S, Claar E, Cozzolino D, Sasso FC, Marrone A, Adinolfi LE, 2 Rinaldi L. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol 2023; 29: 1243-1260 [PMID: 36925456 DOI: 10.3748/wjg.v29.i8.1243]
- 3 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382 [PMID: 11882759 DOI: 10.1097/0000658-200203000-00009]
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of 4 Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- 5 Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235 [PMID: 16432356 DOI:



10.1097/01.sla.0000197706.21803.a1]

- Gao YX, Ning QQ, Yang PX, Guan YY, Liu PX, Liu ML, Qiao LX, Guo XH, Yang TW, Chen DX. Recent advances in recurrent 6 hepatocellular carcinoma therapy. World J Hepatol 2023; 15: 460-476 [PMID: 37206651 DOI: 10.4254/wjh.v15.i4.460]
- Wang D, Xiao M, Wan ZM, Lin X, Li QY, Zheng SS. Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges. 7 World J Gastrointest Surg 2023; 15: 544-552 [PMID: 37206072 DOI: 10.4240/wjgs.v15.i4.544]
- Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol 2019; 20: e262-e273 [PMID: 31044724 8 DOI: 10.1016/S1470-2045(19)30149-4]
- Christou CD, Tsoulfas G. Challenges and opportunities in the application of artificial intelligence in gastroenterology and hepatology. World J 9 Gastroenterol 2021; 27: 6191-6223 [PMID: 34712027 DOI: 10.3748/wjg.v27.i37.6191]
- 10 Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, Zhu J, Marrero JA, Waljee AK. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013; 108: 1723-1730 [PMID: 24169273 DOI: 10.1038/ajg.2013.332]
- Pickett KL, Suresh K, Campbell KR, Davis S, Juarez-Colunga E. Random survival forests for dynamic predictions of a time-to-event outcome 11 using a longitudinal biomarker. BMC Med Res Methodol 2021; 21: 216 [PMID: 34657597 DOI: 10.1186/s12874-021-01375-x]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

